These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 20307650)
1. N-acetyl-L-methionyl-L-Dopa-methyl ester as a dual acting drug that relieves L-Dopa-induced oxidative toxicity. Minelli A; Conte C; Prudenzi E; Cacciatore I; Cornacchia C; Taha E; Pinnen F Free Radic Biol Med; 2010 Jul; 49(1):31-9. PubMed ID: 20307650 [TBL] [Abstract][Full Text] [Related]
2. Neuroprotective and neurotoxic roles of levodopa (L-DOPA) in neurodegenerative disorders relating to Parkinson's disease. Kostrzewa RM; Kostrzewa JP; Brus R Amino Acids; 2002; 23(1-3):57-63. PubMed ID: 12373519 [TBL] [Abstract][Full Text] [Related]
3. Protection of dopaminergic neurons in primary culture by lisuride. Gille G; Rausch WD; Hung ST; Moldzio R; Ngyuen A; Janetzky B; Engfer A; Reichmann H J Neural Transm (Vienna); 2002 Feb; 109(2):157-69. PubMed ID: 12075855 [TBL] [Abstract][Full Text] [Related]
4. Differential effects of l-DOPA on monoamine metabolism, cell survival and glutathione production in midbrain neuronal-enriched cultures from parkin knockout and wild-type mice. Casarejos MJ; Solano RM; Menéndez J; Rodríguez-Navarro JA; Correa C; García de Yébenes J; Mena MA J Neurochem; 2005 Aug; 94(4):1005-14. PubMed ID: 16000163 [TBL] [Abstract][Full Text] [Related]
5. Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study. Shin JY; Park HJ; Ahn YH; Lee PH J Neurochem; 2009 Nov; 111(4):1042-50. PubMed ID: 19765187 [TBL] [Abstract][Full Text] [Related]
6. Intervention of mitochondrial dysfunction-oxidative stress-dependent apoptosis as a possible neuroprotective mechanism of α-lipoic acid against rotenone-induced parkinsonism and L-dopa toxicity. Abdin AA; Sarhan NI Neurosci Res; 2011 Dec; 71(4):387-95. PubMed ID: 21889550 [TBL] [Abstract][Full Text] [Related]
7. Molecular mechanism underlying the cerebral effect of Gly-Pro-Glu tripeptide bound to L-dopa in a Parkinson's animal model. Minelli A; Conte C; Cacciatore I; Cornacchia C; Pinnen F Amino Acids; 2012 Sep; 43(3):1359-67. PubMed ID: 22218995 [TBL] [Abstract][Full Text] [Related]
8. Levodopa: effect on cell death and the natural history of Parkinson's disease. Olanow CW Mov Disord; 2015 Jan; 30(1):37-44. PubMed ID: 25502620 [TBL] [Abstract][Full Text] [Related]
9. L-DOPA: a scapegoat for accelerated neurodegeneration in Parkinson's disease? Lipski J; Nistico R; Berretta N; Guatteo E; Bernardi G; Mercuri NB Prog Neurobiol; 2011 Sep; 94(4):389-407. PubMed ID: 21723913 [TBL] [Abstract][Full Text] [Related]
10. l-3,4-dihydroxyphenylalanine (l-DOPA) modulates brain iron, dopaminergic neurodegeneration and motor dysfunction in iron overload and mutant alpha-synuclein mouse models of Parkinson's disease. Billings JL; Gordon SL; Rawling T; Doble PA; Bush AI; Adlard PA; Finkelstein DI; Hare DJ J Neurochem; 2019 Jul; 150(1):88-106. PubMed ID: 30716176 [TBL] [Abstract][Full Text] [Related]
11. L-Dopa methyl ester--a candidate for chronic systemic delivery of L-Dopa in Parkinson's disease. Cooper DR; Marrel C; Testa B; van de Waterbeemd H; Quinn N; Jenner P; Marsden CD Clin Neuropharmacol; 1984; 7(1):89-98. PubMed ID: 6704979 [TBL] [Abstract][Full Text] [Related]
12. L-DOPA up-regulates glutathione and protects mesencephalic cultures against oxidative stress. Han SK; Mytilineou C; Cohen G J Neurochem; 1996 Feb; 66(2):501-10. PubMed ID: 8592119 [TBL] [Abstract][Full Text] [Related]
13. L-dopa therapy for Parkinson's disease: past, present, and future. Nagatsua T; Sawadab M Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S3-8. PubMed ID: 19131039 [TBL] [Abstract][Full Text] [Related]
14. A multi-biomarker analysis of the antioxidant efficacy of Parkinson's disease therapy. Colamartino M; Duranti G; Ceci R; Sabatini S; Testa A; Cozzi R Toxicol In Vitro; 2018 Mar; 47():1-7. PubMed ID: 29080800 [TBL] [Abstract][Full Text] [Related]
17. Selegiline normalizes, while l-DOPA sustains the increased number of dopamine neurons in the olfactory bulb in a 6-OHDA mouse model of Parkinson's disease. Chiu WH; Carlsson T; Depboylu C; Höglinger GU; Oertel WH; Ries V Neuropharmacology; 2014 Apr; 79():212-21. PubMed ID: 24291466 [TBL] [Abstract][Full Text] [Related]
18. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677 [TBL] [Abstract][Full Text] [Related]
19. Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr. Lees AJ; Tolosa E; Olanow CW Mov Disord; 2015 Jan; 30(1):19-36. PubMed ID: 25488030 [TBL] [Abstract][Full Text] [Related]
20. Impaired behavioural and molecular adaptations to dopamine denervation and repeated L-DOPA treatment in Nur77-knockout mice. St-Hilaire M; Bourhis E; Lévesque D; Rouillard C Eur J Neurosci; 2006 Aug; 24(3):795-805. PubMed ID: 16930409 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]